Desmin cardiac myopathy: molecular pathogenesis and novel treatment concepts
Zusammenfassung der Projektergebnisse
Mutations of the human desmin gene on chromosome 2q35 cause autosomal-dominant and -recessive myopathies and cardiomyopathies. To date no curative therapy is available for this progressive and often lethal disorder. In the current project we addressed the molecular pathophysiology of the disease and performed a preclinical evaluation of AAV9-mediated gene therapy approaches for the cardiomyopathy in recessive desminopathies. A first major contribution of our project work was the successful generation and characterization of hetero- and homozygous R349P desmin knock-in mice, which serve as real patient-mimicking mouse models for both the autosomal-dominant and the autosomal-recessive human desminopathies with maintained desmin protein expression, respectively. Both, hetero- and homozygous R349P knock-in mice develop cardiomyopathy as well as increased susceptibility for cardiac arrhythmias and conduction defects. In extension to our initial workplan, we put an additional work focus on the analysis of the cardiac pathology in desmin knock-out mice (model for autosomal-recessive human desminopathies with lack of desmin protein) and in mdx mice (model for X-linked Duchenne muscular dystrophy and cardiomyopathy) as well as the skeletal muscle pathology in human desminopathies and our R349P desmin knock-in mice. The desmin knock-out mice were primarily used for our first AAV9-mediated desmin gene transfer experiments. A dose of 3x10^12 AAV9-wild-type desmin vector genomes led to a partial reconstitution of wild-type desmin protein expression, which was accompanied by reduced cardiac fibrosis and improved systolic left-ventricular function. Notably, a higher dose of 5x10^12 AAV9-wild-type desmin vector genomes resulted in a full desmin reconstitution in the heart in combination with a nearly complete normalization of the key morphological and functional cardiac parameters. Thus, the highdose AAV9-mediated desmin gene transfer may be a novel and promising therapeutic approach for patients with cardiomyopathy due to the complete lack of desmin protein expression. However, the highdose AAV9-mediated reconstitution of wild-type desmin expression in the hearts of our homozygous R349P desmin knock-in mice did not improve the morphological and functional cardiac parameters but instead showed a tendency to worsen the outcome parameters. Furthermore, we could demonstrate that the AAV9-mediated overexpression of αB-crystallin resulted in a significant improvement of hemodynamic cardiac parameters in treated mdx mice. In contrast, our AAV9-mediated gene transfer of the R16C desmin head and the K449T tail domain mutations into adult wild-type mice apparently did not yield in a high enough expression level to cause disease-specific morphometric, histological and echocardiographic pathologies. Our studies on the skeletal muscle pathology further demonstrated that the expression of mutant desmin causes a multi-level pathology, which primarily affects the extrasarcomeric desmin intermediate filament cytoskeleton and subsequently leads to disturbances of the alignment and orientation of myofibrils, the localization, morphology and function of mitochondria, the structural integrity of neuromuscular junctions as well as the biomechanical stress resistance of muscle fibers. Taken together, our project provided substantial new insights into the molecular pathophysiology of desminrelated cardiomyopathies and myopathies and, moreover, paved the way towards novel gene therapy approaches for the treatment of autosomal-recessive desminopathies with a lack of desmin protein expression.
Projektbezogene Publikationen (Auswahl)
- Desminopathies. In: Goebel HH, Sewry CA, Weller RO (eds). Muscle Disease: Pathology and Genetics. 2nd edition. ISN Neuropath Press 2013. ISBN 978-0-470-67205-1
Schröder R, Clemen CS
(Siehe online unter https://doi.org/10.1002/9781118635469.ch20) - Desminopathies: pathology and mechanisms. Acta Neuropathol 2013 125:47-75
Clemen CS, Herrmann H, Strelkov SV, Schröder R
(Siehe online unter https://doi.org/10.1007/s00401-012-1057-6) - Differential proteomic analysis of abnormal intramyoplasmic aggregates in desminopathy. J Proteomics 2013; 90:14-27
Maerkens A, Kley RA, Olivé M, Theis V, van der Ven PF, Reimann J, Milting H, Schreiner A, Uszkoreit J, Eisenacher M, Barkovits K, Güttsches AK, Tonillo J, Kuhlmann K, Meyer HE, Schröder R, Tegenthoff M, Fürst DO, Müller T, Goldfarb LG, Vorgerd M, Marcus K
(Siehe online unter https://doi.org/10.1016/j.jprot.2013.04.026) - In vivo characterization of human myofibrillar myopathy genes in zebrafish. Biochem Biophys Res Commun 2015; 461:217-223
Bührdel JB, Hirth S, Keßler M, Westphal S, Forster M, Manta L, Wiche G, Schoser B, Schessl J, Schröder R, Clemen CS, Eichinger L, Fürst DO, van der Ven PFM, Rottbauer W, Just S
(Siehe online unter https://doi.org/10.1016/j.bbrc.2015.03.149) - The toxic effect of R350P mutant desmin in striated muscle of man and mouse. Acta Neuropathol 2015; 129:297-315
Clemen CS, Stöckigt F, Strucksberg K-H, Chevessier F, Winter L, Schütz J, Bauer R, Thorweihe J- M, Wenzel D, Schlötzer-Schrehardt U, Rasche V, Krsmanovic P, Katus HA, Rottbauer W, Just S, Müller OJ, Friedrich O, Meyer R, Herrmann H, Schrickel JW, Schröder R
(Siehe online unter https://doi.org/10.1007/s00401-014-1363-2) - AAV9‐mediated gene transfer of desmin ameliorates cardiomyopathy in desmin deficient mice. Gene Ther 2016; 23:673-679
Heckmann M, Bauer R, Jungmann A, Winter L, Rapti K, Strucksberg K-H, Clemen CS, Li Z, Schröder R, Katus H, Müller O
(Siehe online unter https://doi.org/10.1038/gt.2016.40) - Challenges in gene therapy for desminopathies. Cell Gene Therapy Insights 2016 2:403-406
Heckmann MB, Katus HA, Müller OJ
(Siehe online unter https://doi.org/10.18609/cgti.2016.052) - Mutant desmin substantially perturbs mitochondrial morphology, function and maintenance in skeletal muscle tissue. Acta Neuropathol 2016; 132:453-473
Winter L, Wittig I, Peeva V, Eggers B, Heidler J, Chevessier F, Kley RA, Barkovits K, Strecker V, Berwanger C, Herrmann H, Marcus K, Kornblum C, Kunz WS, Schröder R, Clemen CS
(Siehe online unter https://doi.org/10.1007/s00401-016-1592-7) - Neuromuscular endplate pathology in recessive desminopathies: Lessons from man and mice. Neurology 2016; 87:799-805.
Durmus H, Ayhan O, Cirak S, Deymeer F, Parman Y, Franke A, Eiber N, Chevessier F, Schlötzer‐ Schrehardt U, Clemen CS, Hashemolhosseini S, Schröder R, Hemmrich-Stanisak G, Tolun A, Serdaroglu-Oflazer P
(Siehe online unter https://doi.org/10.1212/WNL.0000000000003004) - Early signs of architectural and biomechanical failure in isolated myofibers and immortalized myoblasts from desmin-mutant knock-in mice. Sci Rep 2017; 7:1391
Diermeier S, Iberl J, Vetter K, Haug M, Pollmann C, Reischl B, Buttgereit A, Schürmann S, Spörrer M, Goldmann WH, Fabry B, Elhamine F, Stehle R, Pfitzer G, Winter L, Clemen CS, Herrmann H, Schröder R, Friedrich O
(Siehe online unter https://doi.org/10.1038/s41598-017-01485-x) - Pre-aged remodelling of myofibrillar cytoarchitecture in skeletal muscleexpressing R349P mutant R349P desmin. Neurobiol Aging 2017; 13;58:77-87
Diermeier S, Buttgereit A, Schürmann S, Xu H, Murphy RM, Clemen CS, Schröder R, Friedrich O
(Siehe online unter https://doi.org/10.1016/j.neurobiolaging.2017.06.001)
